In response to high glucose levels, ACLY is acetylated at K540, K546, and K554 by lysine acetyltransferase (KAT2B), reducing the binding between ACLY and the RING-type E3 ubiquitin ligase UBR4, thereby promoting lung cancer progression. The gene discussed is ACLY; the disease is lung carcinoma.